EL SEGUNDO, Calif. (AP) — Los Angeles Chargers running back J.K Dobbins is unlikely to play against the Atlanta Falcons this week because of a knee injury. Dobbins was hurt in the first half of the Chargers’ 30-23 loss to the Baltimore Ravens on Monday night. He had six carries for 40 yards and three catches for 19 yards before leaving the game. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.nanamica Introduces Thermoregulating KODENSHI Wool Sweater and Vest

NoneTherapeuticsMD Inc. stock underperforms Monday when compared to competitors

ALLO-316 in Advanced CD70-Positive ccRCC | Image Credit: © Cornflakesei - stock.adobe.com ALLO-316, an allogeneic CD70-directed CAR T-cell therapy, demonstrated preliminary activity and a manageable safety profile in patients with advanced or metastatic CD70-positive clear cell renal cell carcinoma (ccRCC), according to findings from the phase 1a portion of the phase 1a/1b TRAVERSE trial (NCT04696731) presented at the 2024 SITC Annual Meeting . Among the 39 patients enrolled, 26 were CD70 positive and evaluable for efficacy outcomes, with the highest responses observed in patients with a tumor proportion score (TPS) of at least 50 (n = 21). Tumor reduction was notably greater in CD70-positive patients with a TPS of at least 50, with 76% of patients (n = 16) achieving tumor burden reductions and 33% of patients (n = 7) experiencing a reduction of greater than 30%. Dose-limiting toxicities (DLTs) were observed in 2 patients, both of whom received FCA (fludarabine, cyclophosphamide, and alemtuzumab [Lemtrada]) lymphodepletion followed by ALLO-316 at dose level 2 (DL2). These DLTs were autoimmune hepatitis (n = 1) and cardiogenic shock in the setting of multiorgan failure (n = 1). Treatment-emergent adverse effects (TEAEs) were observed in all 39 patients, with 81% of patients experiencing grade 3 or higher TEAEs. The most common TEAEs included cytokine release syndrome (CRS; any-grade, 62%; grade ≥ 3, 3%), fatigue (59%; 3%), and neutropenia (56%; 51%). No graft-vs-host disease was reported In the poster, lead study author Samer Srour, MS, MD, and coauthors, explained, “observed responses, including ongoing and deepening responses, in patients with a CD70 TPS [of at least] 50%, [indicate] a single infusion of ALLO-316 could benefit patients with immune checkpoint inhibitor– and TKI-relapsed/refractory RCC.” Srour is an assistant professor in the Department of Stem Cell Transplantation and Cellular Therapy in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. Phase 1a of the trial employed a standard dose-escalation design to primarily evaluate DLTs and the incidence of AEs. Phase 1b primarily focused on identifying the recommended phase 2 dose of ALLO-316, establishing the optimal CD70 TPS cutoff, and assessing the incidence of AEs. Secondary end points across both phases included assessments of objective response rate (ORR), complete response rate, duration of response, time to response, progression-free survival, CAR expansion kinetics, and CD70 expression on tumor cells. Patients older than 18 years of age were eligible for enrollment in the TRAVERSE study and were required to have progressive advanced or metastatic ccRCC following prior immune checkpoint inhibitor and VEGF-targeted therapy. Additional enrollment criteria included an ECOG performance status of 0 or 1, adequate organ function, and no untreated central nervous system metastases. CD70 expression was assessed via immunohistochemistry on archival or fresh tumor tissue to confirm eligibility. Patients received lymphodepletion from days –5 to –3, followed by a single infusion of ALLO-316 on day 0. The trial included comprehensive follow-up to assess safety and efficacy through 60 months. The median patient age was 60 years (range, 35-70), and most patients were male (90%). Regarding performance status, 56% of patients had an ECOG PS of 0 or 1. Nearly all patients had stage IV disease (97%), and 82% of patients had undergone prior nephrectomy. The median time since original diagnosis was 43 months (range, 12-216), and the median number of prior therapy lines was 3 (range, 1-8). All patients had received prior anti–PD-1 therapy, and 1 patient had received anti–PD-L1 therapy. Sixty-four percent of patients had received prior anti–CTLA-4 therapy. All patients had received at least 1 prior TKI, 59% of patients had received at least 2 prior TKIs, and 28% of patients had received at least 3 prior TKIs. Additionally, 79% of patients had been previously treated with cabozantinib (Cabometyx), and 8% of patients had progressive disease despite anti–CTLA-4, anti–PD-1, TKI, and belzutifan (Welireg) therapy. CD70 positivity was observed in 79% of patients, with 77% of patients having high TPS (≥ 50%) and 23% of patients having low TPS (< 50%). CD70-negative or -unknown status was reported in 21% of patients. Based on the International Metastatic RCC Database Consortium risk categories, 33% of patients were classified as favorable risk, 51% of patients were classified as intermediate risk, and 10% of patients were classified as poor risk. The median time from enrollment to lymphodepletion was 5 days (range, 1-10), and the median duration of follow-up was 6.8 months (range, 0.4-36.8). Among the 39 enrolled patients, 35 received ALLO-316, and 34 were evaluable for disease outcomes. Stratification was based on CD70 expression, with 26 patients identified as CD70 positive. These patients received treatment across 4 dose levels of ALLO-316. At dose level 1 (40 x 106 cells), 3 patients were treated following FCA lymphodepletion. DL2 (80 x 106 cells) included 16 patients, with 5 receiving FCA and 3 receiving FC300 lymphodepletion. Eight patients are planned to receive FC500 lymphodepletion at DL2 in the phase 1b portion of the trial. Dose level 3 (120 x 106 cells) included 6 patients who were evenly split between the FC300 and FC500 lymphodepletion regimens, whereas dose level 4 (240 x 106 cells) included 1 patient treated with FC300 lymphodepletion. Five patients were CD70 negative, and 3 patients had unknown CD70 expression. These patients received treatment across various dose levels but were not included in the primary efficacy analysis. In the CD70-positive cohort, the best ORR was 27% (n = 7), and responses were exclusively observed in patients with a TPS of at least 50. Confirmed responses were achieved in 24% (n = 5) of these patients. In the FCA cohort (n = 8), a single confirmed response was observed in 1 patient with a high TPS (13%). In the FC cohort (n = 18), the ORR was 33% (n = 6), with confirmed responses reported in 22% of patients (n = 4). Patients treated at DL2 with FC500 had an ORR of 38% (n = 3), with confirmed responses in 25% of patients (n = 2). In this cohort, 2 patients (25%) had durable responses lasting beyond 4 months. Other common TEAEs included decreased white blood cell (WBC) counts (any-grade, 54%; grade ≥ 3, 49%), anemia (51%; 33%), nausea (51%; 0%), thrombocytopenia (46%; 26%), pyrexia (41%; 5%). AEs of special interest included infections (any-grade, 62%; grade ≥ 3, 31), including viral infections (33%; 5%); neurotoxicity (44%; 8%), including headache (21%; 0%); and immune effector cell–associated hemophagocytosis-like syndrome (IEC-HS; 13%; 3%). Immune effector cell–associated neurotoxicity syndrome (ICANS) occurred in 8% of patients, although no grade 3 or higher ICANS was reported. Investigators outlined recommended IEC-HA management guidance, which included ruxolitinib (Jakafi) and the consideration of dexamethasone with or without anakinra (Kineret) in the frontline setting. If responses were insufficient within 24 to 48 hours, recommended second-line therapy consisted of the addition of dexamethasone with or without anakinra (if not already added in the frontline setting); if no improvement was observed after 24 hours, dosing of ruxolitinib/dexamethasone/anakinra could be escalated. If second-line responses were insufficient within 24 to 48 hours, third-line treatment could consist of emapalumab (Gamifant) or etoposide and/or an “off switch” for adoptive cellular therapy. Fatal treatment-related AEs included cardiogenic shock (a DLT), sepsis, and failure to thrive in 1 patient 16 months after their last treatment. TEAEs observed among patients treated at DL2 who received FC500 lymphodepletion (n = 11), were consistent with those seen in the overall population. In this population, the most frequently observed TEAEs were CRS (any-grade, 73%; grade ≥ 3, 0%), fatigue (18%; 0%), neutropenia (64%; 64%), decreased WBC counts (73%; 73%), anemia (64%; 46%), and thrombocytopenia (64%; 27%). Vector copy number (VCN) levels were evaluated over time in peripheral blood and tumor biopsy samples. In responders, VCN levels peaked between approximately days 7 and 21 following CAR T-cell infusion and declined gradually beyond day 56. In contrast, nonresponders exhibited lower VCN levels with minimal expansion over the same period. Tumor biopsy samples showed high VCN levels, highlighting the targeted infiltration of ALLO-316 into the tumor microenvironment. The Dagger effect was characterized by the elimination of CD70-positive host T cells in all evaluable patients by day 10. In contrast, levels of CD70-negative host T cells were generally preserved. This effect was accompanied by robust expansion of ALLO-316 CAR T cells, as evidenced by flow cytometry. By day 56, recovery of CD70-positive host T cells was observed, coinciding with contraction of CAR T cells. “The CD70 CAR-intrinsic Dagger effect promotes robust expansion and persistence of ALLO-316 with standard FC lymphodepletion, highlighting the potential of Dagger technology as the next-generation allogeneic platform,” the authors concluded. “The phase 1 TRAVERSE study supports further evaluation of ALLO-316 in CD70-positive ccRCC and other CD70-positive malignancies. Enrollment is ongoing at the phase 1b dose regimen of FC500 and 80 x 10 6 CAR T cells.” Srour SA, Chahoud J, Drakaki A , et al. ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC): updated safety and efficacy from the phase 1 TRAVERSE multicenter study. J Immunother Cancer . 2024;12(suppl 2). doi:10.1136/jitc-2024-SITC2024.0322Sealed Air Corp. stock rises Monday, still underperforms market

NEW YORK — There's a Christmas Day basketball game at Walt Disney World, featuring Mickey, Minnie, Goofy and Wemby. An animated game, anyway. The real game takes place at Madison Square Garden, where Victor Wembanyama and the San Antonio Spurs face the New York Knicks in a game televised on ABC and ESPN and streamed on Disney+ and ESPN+. The special alt-cast, the first animated presentation of an NBA game, will be shown on ESPN2 and also stream on Disney+ and ESPN+. Madison Square Garden is a staple of the NBA's Christmas schedule. Now it merges with a bigger home of the holidays, because the "Dunk the Halls" game will be staged at Disney, on a court set up right smack in the middle of where countless families have posed for vacation photos. Why that location? Because it was Mickey Mouse's Christmas wish. "Basketball courts often have the ability to make a normal environment look special, but in Disney it can only turn out incredible," Wembanyama said in an ESPN video promoting his Christmas debut. The story — this is Disney, after all — begins with Mickey penning a letter to Santa Claus, asking if he and his pals can host a basketball game. They'll not only get to watch one with NBA players, but some of them will even get to play. Goofy and Donald Duck will sub in for a couple Knicks players, while Mickey and Minnie Mouse will come on to play for the Spurs. "It looks to me like Goofy and Jalen Brunson have a really good pick-and-roll at the elite level," said Phil Orlins, an ESPN vice president of production. Walt Disney World hosted real NBA games in 2020, when the league set up there to complete its season that had been suspended by the COVID-19 pandemic. Those games were played at the ESPN Wide World of Sports. The setting for the Christmas game will be Main Street USA, at the entrance of the Magic Kingdom. Viewers will recognize Cinderella's castle behind one baseline and the train station at the other end, and perhaps some shops they have visited in between. Previous alternate animated broadcasts included an NFL game taking place in Andy's room from "Toy Story;" the "NHL Big City Greens Classic" during a game between the Washington Capitals and New York Rangers; and earlier this month, another NFL matchup between the Cincinnati Bengals and Dallas Cowboys also taking place at Springfield's Atoms Stadium as part of "The Simpsons Funday Football." Unlike basketball, the players are helmeted in those sports. So, this telecast required an extra level of detail and cooperation with players and teams to create accurate appearances of their faces and hairstyles. "So, this is a level of detail that we've never gone, that we've never done on any other broadcast," said David Sparrgrove, the senior director of creative animation for ESPN. Wembanyama, the 7-foot-3 phenom from France who was last season's NBA Rookie of the Year, looks huge even among most NBA players. The creators of the alternate telecast had to design how he'd look not only among his teammates and rivals, but among mice, ducks and chipmunks. "Like, Victor Wembanyama, seeing him in person is insane. It's like seeing an alien descend on a basketball court, and I think we kind of captured that in his animated character," said Drew Carter, who will again handle play-by-play duties, as he had in the previous animated telecasts, and will get an assist from sideline reporter Daisy Duck. Wembanyama's presence is one reason the Spurs-Knicks matchup, the leadoff to the NBA's five-game Christmas slate, was the obvious choice to do the animated telecast. The noon EST start means it will begin in the early evening in France and should draw well there. Also, it comes after ABC televises the "Disney Parks Magical Christmas Day Parade" for the previous two hours, providing more time to hype the broadcast. Recognizing that some viewers who then switch over to the animated game may be Disney experts but NBA novices, there will be 10 educational explainers to help with basketball lingo and rules. Beyond Sports' visualization technology and Sony's Hawk-Eye tracking allow the animated players to make the same movements and plays made moments earlier by the real ones at MSG. Carter and analyst Monica McNutt will be animated in the style of the telecast, donning VR headsets to experience the game from Main Street, USA. Other animated faces recognizable to some viewers include NBA Commissioner Adam Silver, who will judge a halftime dunk contest among Mickey and his friends, and Santa himself, who will operate ESPN's "SkyCam" during the game. The players are curious how the production — and themselves — will look. "It's going to be so crazy to see the game animated," Spurs veteran Chris Paul said. "I think what's dope about it is it will give kids another opportunity to watch a game and to see us, basically, as characters." Get local news delivered to your inbox!

More Biden judges will be confirmed, but four appeals court nominees won’t see a vote under Senate dealFLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company’s inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Q3 Form 10-Q”). Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively. The Company is required to submit to Nasdaq a plan to regain compliance with respect to its delinquent report by no later than January 20, 2025, and if accepted, the Company has until May 13, 2025, to implement the plan to regain compliance. The Company intends to submit a plan to Nasdaq by no later than January 20, 2025 and will evaluate available options to regain compliance within the compliance period. However, there can be no assurance that Nasdaq will accept the plan, the Company will regain compliance within the compliance period, or maintain compliance with the other Nasdaq listing requirements. While the Company has made significant progress in improving its financial reporting infrastructure, these enhancements have required time to implement effectively. The filing delay of the Q3 Form 10-Q primarily results from the backlog associated with the Company’s efforts to become current on its previous filings, including the Forms 10-Q for the first and second quarters of 2024, which were filed recently. “We acknowledge the challenges associated with our recent delays, but we remain committed to ensuring robust and timely financial reporting,” said Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO of Celularity. “We are nearing the completion of the Q3 Form 10-Q and expect to file it shortly. The improvements we have made to our finance function are setting the stage for long-term success, and we are committed to maintaining compliance going forward.” About Celularity Celularity Inc. (Nasdaq: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies. For more information, visit www.celularity.com. Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include express or implied statements regarding the expected timing of the Company’s filing of its quarterly report for the period ending September 30, 2024 on Form 10-Q, the potential submission of a plan to Nasdaq and the potential for Nasdaq to accept such plan or grant the Company an exception period, and the Company’s ability to regain compliance with the Nasdaq continued listing standards. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: the Company’s liquidity situation; the volatility in the Company’s stock price; inherent risks in biotechnological development, including with respect to the development of novel advanced biomaterials; and the regulatory approval process; along with those risk factors set forth under the caption “Risk Factors” in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on July 30, 2024, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company does not presently know, or that the Company currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect the Company’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing the Company’s views as of any subsequent date, and the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor Contact : Carlos Ramirez Senior Vice President, Celularity Inc. Carlos.ramirez@celularity.com Media Contact: Raquel Cona / Michaela Fawcett KCSA Strategic Communications rcona@kcsa.com / mfawcett@kcsa.com

President-elect Donald Trump’s lawyers urge judge to toss his hush money conviction

Aston Villa’s disallowed goal would have counted in England – Unai EmeryBOARDWALKTECH REPORTS SECOND QUARTER FISCAL 2025 FINANCIAL RESULTSCheckers scam warning

Robert Wickens moving up to IMSA GTD series in 2025 thanks to new Bosch hand controls